Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1540-8183.2007.00225.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Time to Catheter-Based Therapy on Outcomes in Acute Pulmonary Embolism.
Circ Cardiovasc Interv
January 2025
Division of Cardiovascular Medicine (E.Y., L.E., J.M.H., S.B.), New York University.
Background: The aim of this study was to examine the impact of early versus delayed catheter-based therapies (CBTs) on clinical outcomes in patients with acute intermediate-risk pulmonary embolism (PE).
Methods: This retrospective cohort study analyzed data from 2 academic centers involving patients with intermediate-risk PE from January 2020 to January 2024. Patients were divided into early (<12 hours) and delayed CBT (≥12 hours) groups.
Acute coronary syndrome due to coronary aneurysm thrombosis as a late complication of Kawasaki disease.
Med Clin (Barc)
January 2025
Departamento de Cardiología, Hospital Universitario Virgen del Rocío, Sevilla, España.
A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial.
JACC Cardiovasc Interv
January 2025
Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China. Electronic address:
Background: First-generation bioresorbable scaffolds (BRS) increased risks of stent thrombosis and adverse events. The Bioheart scaffold is a new poly-L-lactic acid-based BRS.
Objectives: This study sought to evaluate the efficacy and safety of the BRS in patients with coronary artery disease.
Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program.
JACC Cardiovasc Interv
January 2025
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Background: The risk-benefit ratio of the Absorb bioresorbable vascular scaffold (BVS) may vary before and after 3 years, the time point of complete bioresorption of the poly-L-lactic acid scaffold.
Objectives: The aim of this study was to determine the time-varying outcomes of the Absorb BVS compared with cobalt-chromium everolimus-eluting stents (EES) from a large individual-patient-data pooled analysis of randomized trials.
Methods: The individual patient data from 5 trials that randomized 5,988 patients undergoing percutaneous coronary intervention to the Absorb BVS vs EES with 5-year follow-up were pooled.
Kounis syndrome manifesting with myocardial infarction due to bi-coronary late stent thrombosis following anaphylaxis.
J Invasive Cardiol
January 2025
Klinikum Fürth, Department of Cardiology and Pneumology, Academic Teaching Hospital of the Friedrich-Alexander-University Erlangen-Nuremberg, Fürth, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!